Related Experiment Video
Updated: Oct 5, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells
Y Matsumoto1, H Takano, K Kunishio
1Department of Neurological Surgery, Kagawa Medical University, Miki-cho, Kita-gun, Kagawa 761-0793, Japan. mizaya@kms.ac.jp
Abstract:
The cell lines described in the present study were isolated as part of an effort to understand resistance to topoisomerase (topo) II inhibitors. To that end, 50 sublines were isolated from four human breast cancer cell lines, i.e., MCF-7, T47D, MDA-MB-231, and ZR-75B. As an initial step, a concentration that would be lethal to the majority of cells (IC99) was selected for both VP-16 and mAMSA, for each cell line. The identification of an increasing number of putative drug resistance-related proteins provided the opportunity to examine expression of the corresponding genes in the selected cell lines. Northern blot analysis revealed different responses to the selecting agents in the different cell lines. Previous studies examining expression of multidrug resistance (MDR)-1 in resistant cell lines had found undetectable levels in all cells. In the ZR-75B sublines, increased expression of MDR-associated protein (MRP) and canalicular multispecific organic anion transporter (cMOAT) was observed, and when the relative levels of overexpression were compared, a high correlation was found. In contrast, increased expression of MRP was observed in some of the MDA-MB-231 sublines, without a concomitant increase in cMOAT expression. Finally, in both T47D and MCF-7 sublines, increased expression of cMOAT or MRP was observed infrequently, and where it occurred, was of a much smaller magnitude. In the analysis of expression of MRP, the highest levels were found in the ZR-75B and MDA-MB-231 sublines, with lower levels in the MCF-7 and T47D clones. Similarly, differences in the expression of topo IIalpha were observed among the sublines. Although the differences in expression appear to depend on the parental cell line from which the resistant sublines were derived, a strong correlation was observed between the expression of MRP and the levels of topo IIalpha. Cell lines with low levels of MRP had lower levels of topo IIalpha, while those with high levels of MRP maintained higher levels of topo IIalpha. While a reduced topo IIalpha level was common, there did not appear to be a compensating increase in the expression of topo IIbeta or topo I or casein kinase (CK) IIalpha in any of the cell lines. While the possibility that such compensation could occur has been discussed and even reported in some cell lines, such an adaptation was not observed in the present study, suggesting that it is not common.
Insights
This study investigated drug resistance in breast cancer cell lines, finding that increased expression of multidrug resistance-associated protein (MRP) correlates with higher topoisomerase IIalpha levels, suggesting a key mechanism in chemoresistance.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Topoisomerase II (topo II) inhibitors are crucial in cancer chemotherapy.
- Understanding mechanisms of drug resistance is vital for improving treatment efficacy.
- Previous studies on multidrug resistance (MDR)-1 in resistant cell lines showed undetectable levels.
Purpose of the Study:
- To investigate the molecular mechanisms of resistance to topoisomerase II inhibitors in human breast cancer cell lines.
- To examine the expression of drug resistance-related genes, including multidrug resistance-associated protein (MRP) and canalicular multispecific organic anion transporter (cMOAT), in response to VP-16 and mAMSA.
- To explore the correlation between gene expression and topoisomerase IIalpha levels in resistant sublines.
Main Methods:
- Isolation of 50 sublines from four human breast cancer cell lines (MCF-7, T47D, MDA-MB-231, ZR-75B) selected for resistance to VP-16 and mAMSA.
- Northern blot analysis to assess gene expression of MDR-associated protein (MRP), canalicular multispecific organic anion transporter (cMOAT), and topoisomerase IIalpha (topo IIalpha).
- Comparative analysis of gene expression levels across different resistant sublines and correlation with parental cell lines.
Main Results:
- Differential expression of MRP and cMOAT was observed across cell lines; ZR-75B sublines showed high correlation between MRP and cMOAT overexpression.
- MDA-MB-231 sublines exhibited increased MRP without increased cMOAT.
- MCF-7 and T47D sublines showed infrequent and low-magnitude increases in MRP or cMOAT. A strong positive correlation was found between MRP expression and topo IIalpha levels across all sublines.
- No compensatory increase in topoisomerase IIbeta, topoisomerase I, or casein kinase IIalpha was observed.
Conclusions:
- The expression of drug resistance genes like MRP and transporters like cMOAT varies significantly among breast cancer cell lines.
- A strong correlation exists between increased MRP expression and elevated topo IIalpha levels in resistant cell lines.
- These findings suggest that MRP and topo IIalpha modulation are key factors in topoisomerase II inhibitor resistance, with limited evidence for compensatory mechanisms involving other related enzymes.
Related Concept Videos
Treatment Resistant Cancers
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

